8 results match your criteria: "Yale University School of Medicine and Yale Comprehensive Cancer Center[Affiliation]"
Bioessays
May 2023
ICREA-Complex Systems Lab, Universitat Pompeu Fabra, Barcelona, Spain.
Human cancers comprise an heterogeneous array of diseases with different progression patterns and responses to therapy. However, they all develop within a host context that constrains their natural history. Since it occurs across the diversity of organisms, one can conjecture that there is order in the cancer multiverse.
View Article and Find Full Text PDFClin Breast Cancer
October 2021
Department of Radiation Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT. Electronic address:
Introduction: Poor adherence to the 2011 American Society for Radiation Oncology (ASTRO) evidence-based guideline on whole-breast irradiation (WBI) has been reported. We utilized theMednet to assess the views of the updated 2018 guideline among radiation oncologists (ROs).
Methods: We identified 11 questions asked by community ROs on theMednet, a web-based platform, between October 27, 2014 and May 2, 2017 that were updated in the 2018 guideline.
Blood Rev
September 2020
Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, CT, USA; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA. Electronic address:
Patients with acute myeloid leukemia (AML) who achieve morphologic remission in the bone marrow after initial treatment often continue to harbor residual leukemic cells that can give rise to disease relapse. Achievement of a deeper remission has been associated with a reduced risk of relapse and improved event-free and overall survival in several studies. However, standardization of diagnostic techniques, sample acquisition and test timing are needed before minimal, also known as measurable, residual disease (MRD) quantification can be used to guide treatment decision making.
View Article and Find Full Text PDFBlood Rev
September 2019
Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, USA. Electronic address:
Clonal hematopoiesis (CH) as defined by the presence of somatic mutations in genes associated with myeloid neoplasms (MN) is common in healthy elderly individuals and does not necessarily constitute a premalignant state. Several acronyms (idiopathic cytopenia of undetermined significance [ICUS], clonal cytopenia of undetermined significance [CCUS], CH of indeterminate potential [CHIP]) related to CH have been coined to describe patients who do not meet the diagnostic criteria for other hematologic disorders. CHIP carries an annual progression rate to MN of 0.
View Article and Find Full Text PDFSurg Res Pract
April 2017
Department of Surgery, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, CT 06520, USA.
. Most institutions require a patient undergoing sentinel lymph node biopsy to go through nuclear medicine prior to surgery to be injected with radioisotope. This study describes the long-term results using intraoperative injection of radioisotope.
View Article and Find Full Text PDFCancer
May 2014
Section of Pediatric Hematology/Oncology, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, Connecticut.
Background: The authors prospectively assessed anxiety, depression, and behavior in children with standard-risk acute lymphoblastic leukemia (SR-ALL) during the first year of therapy and identified associated risk factors.
Methods: A cohort study was performed of 159 children (aged 2 years-9.99 years) with SR-ALL who were enrolled on Children's Oncology Group protocol AALL0331 at 31 sites.
Proc Natl Acad Sci U S A
October 2002
Department of Pathology, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, CT 06520, USA.
With the advent of drugs targeting specific molecular defects in cancerous cells [Gorre, M. E., et al.
View Article and Find Full Text PDFBone Marrow Transplant
June 1999
Department of Medicine, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, CT, USA.
This is a prospective study designed to determine the toxicity, efficacy and antileukemic effect of high-dose cytosine arabinoside (ara-C), cyclophosphamide and total body irradiation (TBI) as a myeloablative regimen prior to allogeneic bone marrow transplantation for patients with hematologic malignancies. Fifty-eight patients with hematologic malignancies were treated with cyclophosphamide, high-dose ara-C and total body irradiation (TBI) followed by allogeneic bone marrow transplantation. Fifty patients had good prognosis disease and eight had poor prognosis disease.
View Article and Find Full Text PDF